Inovio Pharmaceuticals (NASDAQ:INO) Upgraded at HC Wainwright

Posted by Stanley Muller on Nov 5th, 2026

HC Wainwright upgraded shares of Inovio Pharmaceuticals (NASDAQ:INO – Free Report) from a neutral rating to a buy rating in a report released on Monday morning, Marketbeat.com reports. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at $0.02 EPS, Q4 2027 earnings at $0.12 EPS and FY2027 earnings at ($0.03) EPS.

Several other research analysts have also recently issued reports on the stock. Piper Sandler reiterated an “overweight” rating and set a $4.00 target price on shares of Inovio Pharmaceuticals in a report on Monday, August 3rd. Zacks Research lowered Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, October 12th. Jefferies Financial Group upgraded Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and boosted their target price for the stock from $1.80 to $3.00 in a research note on Thursday, August 13th. Wall Street Zen upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings lowered Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $4.00.

Check Out Our Latest Research Report on INO

Inovio Pharmaceuticals Price Performance

Shares of INO stock opened at $1.62 on Monday. The stock has a 50 day moving average price of $1.17 and a 200 day moving average price of $1.27. Inovio Pharmaceuticals has a 52-week low of $0.56 and a 52-week high of $2.72.

Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) last issued its earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.15. On average, equities analysts anticipate that Inovio Pharmaceuticals will post -0.74 earnings per share for the current fiscal year.

Institutional Trading of Inovio Pharmaceuticals

Several large investors have recently bought and sold shares of INO. Headlands Technologies LLC purchased a new position in shares of Inovio Pharmaceuticals in the second quarter worth $33,000. Engineers Gate Manager LP acquired a new stake in shares of Inovio Pharmaceuticals during the second quarter worth $37,000. Squarepoint Ops LLC lifted its stake in shares of Inovio Pharmaceuticals by 46.5% during the second quarter. Squarepoint Ops LLC now owns 36,391 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 11,554 shares during the period. Prime Capital Investment Advisors LLC grew its holdings in shares of Inovio Pharmaceuticals by 312.4% during the third quarter. Prime Capital Investment Advisors LLC now owns 70,636 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 53,510 shares during the last quarter. Finally, LexAurum Advisors LLC purchased a new stake in shares of Inovio Pharmaceuticals during the third quarter valued at $118,000. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Trending Headlines about Inovio Pharmaceuticals

Here are the key news stories impacting Inovio Pharmaceuticals this week:

Positive Sentiment: The FDA granted accelerated approval to VOCERYQ (INO-3107) for recurrent respiratory papillomatosis (RRP). The treatment is described as the first FDA-approved DNA medicine, potentially validating Inovio’s platform and opening a path to further pipeline opportunities. Article: Inovio: Upgrading To ‘Buy’ On Voceryq Accelerated Approval RRP And Competitive Advantages
Positive Sentiment: HC Wainwright upgraded INO to Buy from Neutral and set a $5 price target. The firm also raised its 2027 EPS outlook, now forecasting a smaller full-year loss of $0.03 per share versus its previous $0.21 estimate, with positive earnings projected for the second half. Article: HC Wainwright Upgrades Inovio Pharmaceuticals to Buy
Neutral Sentiment: VOCERYQ’s commercial prospects remain to be demonstrated. The Seeking Alpha analysis cites competition from Precigen’s PAPZIMEOS, while pointing to possible advantages for VOCERYQ in safety, dosing convenience and injection burden. Article: Inovio: Upgrading To ‘Buy’ On Voceryq Accelerated Approval RRP And Competitive Advantages
Negative Sentiment: After a dramatic post-approval rally, shares have retreated, potentially as investors take profits and weigh the risks of launching a new treatment against competition and execution uncertainty. The approval and analyst upgrade remain supportive, but they do not guarantee commercial uptake. Article: Inovio’s VOCERYQ Data Cut Both Ways as Launch Clock Starts Ticking

About Inovio Pharmaceuticals

(Get Free Report)

Inovio Pharmaceuticals, Inc is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company’s platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells.

Inovio’s product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases.